Listen Now
Topics Covered
- How Diagnostic Technologies Contribute to Your Blood Cancer Treatment Options for Lymphoma, Leukemia, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs)
- New & Emerging Diagnostic Technologies
- The Role of Clinical Trials
- How You May Participate in a Blood Cancer Clinical Trial
- Accessing Resources for Blood Cancer Clinical Trials
- The Role of the Pathologist
- Understanding Your Pathology Reports
- Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, List of Questions, Follow-Up Care & Discussion of OpenNotes
- Quality-of-Life & Lifestyle Concerns
- Questions for Our Panel of Experts
Our Panel of Experts

Peter Martin, MD, MS
Chief Lymphoma Program, Associate Professor of Medicine, Weill Cornell Medicine, Associate Attending Physician, NewYork-Presbyterian Hospital

Michael J. Mauro, MD
Leader, Myeloproliferative Neoplasms Program, Member, Memorial Sloan Kettering Cancer Center, Professor, Weill Cornell Medicine

Ruben A. Mesa, MD, FACP
Executive Director, Mays Cancer Center at UT Health San Antonio MD Anderson, Mays Family Foundation Distinguished University Presidential Chair, Professor of Medicine, Mays Cancer Center – An NCI Designated Cancer Center

Matthew J. Butler, MD
Assistant Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Mays MD Anderson Cancer Center, UT Health San Antonio

Joseph Khoury, MD, FCAP
Professor, Division of Pathology & Lab Medicine, Department of Hematopathology, Medical Director, Clinical Expansion, Division of Pathology & Lab Medicine, Executive Director, MD Anderson Cancer Network, Division of Pathology & Lab Medicine, The University of Texas M. D. Anderson Cancer Center

Sarah Thibault-Sennett, PhD
Senior Manager, Public Policy & Advocacy, Association for Molecular Pathology (AMP)

Carolyn Messner, DSW, BCD, FAPOS, FAOSW
Senior Director of Education and Training, CancerCare
Brochure
You can download the brochure for this workshop
Workshop Date
This workshop was originally recorded on January 31, 2022.